{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT02676765",
      "orgStudyIdInfo": {
        "id": "HM20006291"
      },
      "secondaryIdInfos": [
        {
          "id": "MISP 52707",
          "type": "OTHER_GRANT",
          "domain": "Merck"
        }
      ],
      "organization": {
        "fullName": "Virginia Commonwealth University",
        "class": "OTHER"
      },
      "briefTitle": "Desensitization and Cross-Desensitization During Oral Grass or Ragweed Pollen Immunotherapy",
      "officialTitle": "Desensitization and Cross-Desensitization During Oral Grass or Ragweed Pollen Immunotherapy"
    },
    "statusModule": {
      "statusVerifiedDate": "2022-02",
      "overallStatus": "TERMINATED",
      "whyStopped": "Intellectual property issues with drug manufacture.",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2016-06",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2018-01-18",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2018-01-18",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2016-02-03",
      "studyFirstSubmitQcDate": "2016-02-03",
      "studyFirstPostDateStruct": {
        "date": "2016-02-08",
        "type": "ESTIMATED"
      },
      "resultsFirstSubmitDate": "2022-02-21",
      "resultsFirstSubmitQcDate": "2022-02-21",
      "resultsFirstPostDateStruct": {
        "date": "2022-03-18",
        "type": "ACTUAL"
      },
      "dispFirstSubmitDate": "2021-07-19",
      "dispFirstSubmitQcDate": "2021-07-19",
      "dispFirstPostDateStruct": {
        "date": "2021-07-23",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2022-02-21",
      "lastUpdatePostDateStruct": {
        "date": "2022-03-18",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Virginia Commonwealth University",
        "class": "OTHER"
      }
    },
    "oversightModule": {
      "isFdaRegulatedDrug": true,
      "isFdaRegulatedDevice": false,
      "isUsExport": false
    },
    "descriptionModule": {
      "briefSummary": "The purpose of this study is to determine if sublingual allergen immunotherapy tablets work by inducing a state of desensitization in mast cells and basophils.",
      "detailedDescription": "To induce clinical tolerance, a failure to respond to an allergen to which one was previously responsive, is an important objective for physicians, one that plays a significant role in the primary prevention of allergic reactions in the clinical practice of Allergy \\& Immunology. The tolerance resulting after standard subcutaneous immunotherapy to aeroallergen and insect venom allergens is long lasting and allergen-specific, and may involve antigen-specific T regulatory cells. In contrast, tolerance resulting from drug desensitization protocols is short-lived, and postulated to target mast cells and basophils. Research into the cellular and biochemical processes by which desensitization occurs has revealed that mast cells desensitized to one antigen in vitro, under certain conditions, lose the ability to degranulate to unrelated antigens or to direct FcÎµRI cross-linking. Preliminary data suggests that this cross-desensitization can happen in patients undergoing incremental desensitization, depending in part on the percentage of IgE targeted to the allergen used for desensitization. This proposal therefore aims to explore desensitization and cross-desensitization in human volunteers undergoing standard sublingual (SL) immunotherapy to grass or ragweed pollen.\n\nSubjects will undergo SL immunotherapy with either Timothy or Short Ragweed tablets, taking one tablet per day, or will take a placebo tablet. Titration skin testing to Timothy or Short Ragweed, to one or preferably two additional allergens to which the subject is sensitive, and to codeine as a control for mast cell activation capability through a non-IgE-dependent pathway will be performed to determine the PC3 value (see below). Skin testing, including histamine and diluent controls, will be performed prior to and at one and four weeks after initiation of immunotherapy. At each time point, blood will be obtained to measure total and antigen-specific IgE levels, tryptase and cytokine levels, and basophil activation with the relevant allergens and C5a as a non-IgE-mediated control for basophil activation."
    },
    "conditionsModule": {
      "conditions": [
        "Immunologic Desensitization"
      ],
      "keywords": [
        "Allergic rhinitis",
        "Immunotherapy, Allergen",
        "Sublingual Immunotherapy"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "BASIC_SCIENCE",
        "maskingInfo": {
          "masking": "DOUBLE",
          "whoMasked": [
            "PARTICIPANT",
            "INVESTIGATOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 58,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "sublingual allergen tablets",
          "type": "EXPERIMENTAL",
          "description": "Subjects will be administered a sublingual allergen tablet customized to their individual allergic sensitization.",
          "interventionNames": [
            "Drug: allergen extract tablet"
          ]
        },
        {
          "label": "Placebo",
          "type": "PLACEBO_COMPARATOR",
          "description": "Subjects will be administered placebo sublingual tablets",
          "interventionNames": [
            "Drug: Placebo tablet"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "allergen extract tablet",
          "description": "1 allergen extract tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet",
          "armGroupLabels": [
            "sublingual allergen tablets"
          ],
          "otherNames": [
            "Ragwitek",
            "Grastek"
          ]
        },
        {
          "type": "DRUG",
          "name": "Placebo tablet",
          "description": "1 placebo tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet",
          "armGroupLabels": [
            "Placebo"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Change in PC3",
          "description": "Change in the dose of allergen eliciting a wheal 3 mm greater than negative control upon skin prick testing (PC3)",
          "timeFrame": "Assessed at 2 weeks and at the end of the study (2 months)"
        },
        {
          "measure": "Change in Basophil Activation",
          "description": "Change in the dose of allergen eliciting a 50% increase in number of basophils positive for CD63 and/or CD203c relative to negative and positive controls",
          "timeFrame": "Assessed at 2 weeks and at the end of the study (2 months)"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Cross-desensitization - PC3",
          "description": "Change in the dose of an unrelated allergen eliciting a wheal 3 mm greater than negative control upon skin prick testing (PC3)",
          "timeFrame": "Assessed at 2 weeks and at the end of the study (2 months)"
        },
        {
          "measure": "Cross-desensitization - Basophil Activation",
          "description": "Change in the dose of allergen eliciting a 50% increase in number of basophils positive for CD63 and/or CD203c relative to negative and positive controls",
          "timeFrame": "Assessed at 2 weeks and at the end of the study (2 months)"
        }
      ],
      "otherOutcomes": [
        {
          "measure": "Percent Allergen-specific IgE",
          "description": "The percent of total serum IgE that is specific for the primary allergen will be compared to the degree (if any) of cross-desensitization seen by skin prick or basophil activation testing",
          "timeFrame": "Assessed at enrollment, at 2 weeks, and at the end of the study (2 months)"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Verified allergic sensitivity to either Timothy Grass or Short Ragweed pollen (primary allergen)\n* Verified allergic sensitivity to at least one allergen in addition to the primary allergen\n\nExclusion Criteria:\n\n* Negative skin testing to Timothy Grass or Short Ragweed pollen and at least one other environmental allergen\n* Dermatographism\n* Severe dermatologic condition that may interfere with skin testing\n* Pregnancy\n* H1 receptor antihistamine taken within 7 days of testing\n* Systemic steroids\n* Omalizumab taken at any time in the past\n* Receiving or received allergen immunotherapy\n* Desensitized to any drug within 6 months\n* Current uncontrolled or severe asthma\n* Eosinophilic esophagitis\n* Significant pulmonary, cardiovascular, renal, hepatobiliary, or neurological diseases, or another disease process felt to put a subject at increased risk for adverse events\n* Hypersensitivity to any of the inactive ingredients in the allergen extract tablets\n* History of mental illness or drug or alcohol abuse that could interfere with the ability to comply with study requirements\n* Inability or unwillingness to give written informed consent",
      "healthyVolunteers": true,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Lawrence B Schwartz, M.D.,Ph.D.",
          "affiliation": "Virginia Commonwealth University",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "Virginia Commonwealth University",
          "city": "Richmond",
          "state": "Virginia",
          "zip": "23298",
          "country": "United States",
          "geoPoint": {
            "lat": 37.55376,
            "lon": -77.46026
          }
        }
      ]
    },
    "referencesModule": {
      "references": [
        {
          "pmid": "22009002",
          "type": "BACKGROUND",
          "citation": "Zhao W, Gomez G, Macey M, Kepley CL, Schwartz LB. In vitro desensitization of human skin mast cells. J Clin Immunol. 2012 Feb;32(1):150-60. doi: 10.1007/s10875-011-9605-8. Epub 2011 Oct 19."
        },
        {
          "pmid": "24468255",
          "type": "BACKGROUND",
          "citation": "Maloney J, Bernstein DI, Nelson H, Creticos P, Hebert J, Noonan M, Skoner D, Zhou Y, Kaur A, Nolte H. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. Ann Allergy Asthma Immunol. 2014 Feb;112(2):146-153.e2. doi: 10.1016/j.anai.2013.11.018. Epub 2013 Dec 21."
        },
        {
          "pmid": "23622121",
          "type": "BACKGROUND",
          "citation": "Creticos PS, Maloney J, Bernstein DI, Casale T, Kaur A, Fisher R, Liu N, Murphy K, Nekam K, Nolte H. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. J Allergy Clin Immunol. 2013 May;131(5):1342-9.e6. doi: 10.1016/j.jaci.2013.03.019."
        },
        {
          "pmid": "15575931",
          "type": "BACKGROUND",
          "citation": "Cockcroft DW, Davis BE, Boulet LP, Deschesnes F, Gauvreau GM, O'Byrne PM, Watson RM. The links between allergen skin test sensitivity, airway responsiveness and airway response to allergen. Allergy. 2005 Jan;60(1):56-9. doi: 10.1111/j.1398-9995.2004.00612.x."
        },
        {
          "pmid": "9500760",
          "type": "BACKGROUND",
          "citation": "Niederberger V, Laffer S, Froschl R, Kraft D, Rumpold H, Kapiotis S, Valenta R, Spitzauer S. IgE antibodies to recombinant pollen allergens (Phl p 1, Phl p 2, Phl p 5, and Bet v 2) account for a high percentage of grass pollen-specific IgE. J Allergy Clin Immunol. 1998 Feb;101(2 Pt 1):258-64. doi: 10.1016/s0091-6749(98)70391-4."
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "NO"
    }
  },
  "resultsSection": {
    "participantFlowModule": {
      "preAssignmentDetails": "After enrollment, allergen skin prick testing was performed to confirm sensitization to the required allergens. Of the 58 subjects enrolled, 37 were determined to lack sensitization to timothy grass pollen or ragweed pollen, plus at least one other environmental allergen. These subjects were excluded from the study prior to randomization. One subjected qualified, but was lost to follow up prior to randomizing.",
      "groups": [
        {
          "id": "FG000",
          "title": "Sublingual Allergen Tablets",
          "description": "Subjects will be administered a sublingual allergen tablet customized to their individual allergic sensitization.\n\nallergen extract tablet: 1 allergen extract tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet"
        },
        {
          "id": "FG001",
          "title": "Placebo",
          "description": "Subjects will be administered placebo sublingual tablets\n\nPlacebo tablet: 1 placebo tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet"
        }
      ],
      "periods": [
        {
          "title": "Overall Study",
          "milestones": [
            {
              "type": "STARTED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "10"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "10"
                }
              ]
            },
            {
              "type": "COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "10"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "9"
                }
              ]
            },
            {
              "type": "NOT COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "1"
                }
              ]
            }
          ],
          "dropWithdraws": [
            {
              "type": "Lost to Follow-up",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "1"
                }
              ]
            }
          ]
        }
      ]
    },
    "baselineCharacteristicsModule": {
      "populationDescription": "One subject in placebo arm was lost to follow up and not analyzed.",
      "groups": [
        {
          "id": "BG000",
          "title": "Sublingual Allergen Tablets",
          "description": "Subjects will be administered a sublingual allergen tablet customized to their individual allergic sensitization.\n\nallergen extract tablet: 1 allergen extract tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet"
        },
        {
          "id": "BG001",
          "title": "Placebo",
          "description": "Subjects will be administered placebo sublingual tablets\n\nPlacebo tablet: 1 placebo tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet"
        },
        {
          "id": "BG002",
          "title": "Total",
          "description": "Total of all reporting groups"
        }
      ],
      "denoms": [
        {
          "units": "Participants",
          "counts": [
            {
              "groupId": "BG000",
              "value": "10"
            },
            {
              "groupId": "BG001",
              "value": "10"
            },
            {
              "groupId": "BG002",
              "value": "20"
            }
          ]
        }
      ],
      "measures": [
        {
          "title": "Age, Categorical",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "BG000",
                      "value": "10"
                    },
                    {
                      "groupId": "BG001",
                      "value": "10"
                    },
                    {
                      "groupId": "BG002",
                      "value": "20"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "title": "<=18 years",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Between 18 and 65 years",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "10"
                    },
                    {
                      "groupId": "BG001",
                      "value": "10"
                    },
                    {
                      "groupId": "BG002",
                      "value": "20"
                    }
                  ]
                },
                {
                  "title": ">=65 years",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Sex: Female, Male",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "BG000",
                      "value": "10"
                    },
                    {
                      "groupId": "BG001",
                      "value": "10"
                    },
                    {
                      "groupId": "BG002",
                      "value": "20"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "title": "Female",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "8"
                    },
                    {
                      "groupId": "BG001",
                      "value": "8"
                    },
                    {
                      "groupId": "BG002",
                      "value": "16"
                    }
                  ]
                },
                {
                  "title": "Male",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "2"
                    },
                    {
                      "groupId": "BG001",
                      "value": "2"
                    },
                    {
                      "groupId": "BG002",
                      "value": "4"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Race and Ethnicity Not Collected",
          "populationDescription": "Race and Ethnicity were not collected from any participant.",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG002",
                      "value": "0"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Region of Enrollment",
          "paramType": "NUMBER",
          "unitOfMeasure": "participants",
          "classes": [
            {
              "title": "United States",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "BG000",
                      "value": "10"
                    },
                    {
                      "groupId": "BG001",
                      "value": "10"
                    },
                    {
                      "groupId": "BG002",
                      "value": "20"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "10"
                    },
                    {
                      "groupId": "BG001",
                      "value": "10"
                    },
                    {
                      "groupId": "BG002",
                      "value": "20"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "outcomeMeasuresModule": {
      "outcomeMeasures": [
        {
          "type": "PRIMARY",
          "title": "Change in PC3",
          "description": "Change in the dose of allergen eliciting a wheal 3 mm greater than negative control upon skin prick testing (PC3)",
          "populationDescription": "One subject from placebo arm not analyzed due to missing data",
          "reportingStatus": "POSTED",
          "paramType": "MEDIAN",
          "dispersionType": "Inter-Quartile Range",
          "unitOfMeasure": "Change in log dilution of allergen",
          "timeFrame": "Assessed at 2 weeks and at the end of the study (2 months)",
          "groups": [
            {
              "id": "OG000",
              "title": "Sublingual Allergen Tablets",
              "description": "Subjects will be administered a sublingual allergen tablet customized to their individual allergic sensitization.\n\nallergen extract tablet: 1 allergen extract tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet"
            },
            {
              "id": "OG001",
              "title": "Placebo",
              "description": "Subjects will be administered placebo sublingual tablets\n\nPlacebo tablet: 1 placebo tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "10"
                },
                {
                  "groupId": "OG001",
                  "value": "8"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "-0.2750",
                      "lowerLimit": "-1.5900",
                      "upperLimit": "-0.0200"
                    },
                    {
                      "groupId": "OG001",
                      "value": "-0.0250",
                      "lowerLimit": "-0.5275",
                      "upperLimit": "0.2500"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "Change in Basophil Activation",
          "description": "Change in the dose of allergen eliciting a 50% increase in number of basophils positive for CD63 and/or CD203c relative to negative and positive controls",
          "reportingStatus": "POSTED",
          "paramType": "MEDIAN",
          "dispersionType": "Inter-Quartile Range",
          "unitOfMeasure": "Change in log dilution of allergen",
          "timeFrame": "Assessed at 2 weeks and at the end of the study (2 months)",
          "groups": [
            {
              "id": "OG000",
              "title": "Sublingual Allergen Tablets",
              "description": "Subjects will be administered a sublingual allergen tablet customized to their individual allergic sensitization.\n\nallergen extract tablet: 1 allergen extract tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet"
            },
            {
              "id": "OG001",
              "title": "Placebo",
              "description": "Subjects will be administered placebo sublingual tablets\n\nPlacebo tablet: 1 placebo tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "10"
                },
                {
                  "groupId": "OG001",
                  "value": "9"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "-4.1100",
                      "lowerLimit": "-7.8050",
                      "upperLimit": "-0.7050"
                    },
                    {
                      "groupId": "OG001",
                      "value": "0.1300",
                      "lowerLimit": "-1.9275",
                      "upperLimit": "2.9600"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Cross-desensitization - PC3",
          "description": "Change in the dose of an unrelated allergen eliciting a wheal 3 mm greater than negative control upon skin prick testing (PC3)",
          "reportingStatus": "POSTED",
          "paramType": "MEDIAN",
          "dispersionType": "Inter-Quartile Range",
          "unitOfMeasure": "Change in log dilution of allergen",
          "timeFrame": "Assessed at 2 weeks and at the end of the study (2 months)",
          "groups": [
            {
              "id": "OG000",
              "title": "Sublingual Allergen Tablets",
              "description": "Subjects will be administered a sublingual allergen tablet customized to their individual allergic sensitization.\n\nallergen extract tablet: 1 allergen extract tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet"
            },
            {
              "id": "OG001",
              "title": "Placebo",
              "description": "Subjects will be administered placebo sublingual tablets\n\nPlacebo tablet: 1 placebo tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "10"
                },
                {
                  "groupId": "OG001",
                  "value": "9"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "-0.0350",
                      "lowerLimit": "-1.0250",
                      "upperLimit": "0.3600"
                    },
                    {
                      "groupId": "OG001",
                      "value": "0.8000",
                      "lowerLimit": "-0.1950",
                      "upperLimit": "1.5175"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Cross-desensitization - Basophil Activation",
          "description": "Change in the dose of allergen eliciting a 50% increase in number of basophils positive for CD63 and/or CD203c relative to negative and positive controls",
          "reportingStatus": "POSTED",
          "paramType": "MEDIAN",
          "dispersionType": "Inter-Quartile Range",
          "unitOfMeasure": "Change in log dilution of allergen",
          "timeFrame": "Assessed at 2 weeks and at the end of the study (2 months)",
          "groups": [
            {
              "id": "OG000",
              "title": "Sublingual Allergen Tablets",
              "description": "Subjects will be administered a sublingual allergen tablet customized to their individual allergic sensitization.\n\nallergen extract tablet: 1 allergen extract tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet"
            },
            {
              "id": "OG001",
              "title": "Placebo",
              "description": "Subjects will be administered placebo sublingual tablets\n\nPlacebo tablet: 1 placebo tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "10"
                },
                {
                  "groupId": "OG001",
                  "value": "9"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "-0.2000",
                      "lowerLimit": "-2.3825",
                      "upperLimit": "0.3075"
                    },
                    {
                      "groupId": "OG001",
                      "value": "-0.1500",
                      "lowerLimit": "-5.6625",
                      "upperLimit": "0.7050"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "OTHER_PRE_SPECIFIED",
          "title": "Percent Allergen-specific IgE",
          "description": "The percent of total serum IgE that is specific for the primary allergen will be compared to the degree (if any) of cross-desensitization seen by skin prick or basophil activation testing",
          "reportingStatus": "NOT_POSTED",
          "timeFrame": "Assessed at enrollment, at 2 weeks, and at the end of the study (2 months)",
          "denomUnitsSelected": "Participants"
        }
      ]
    },
    "adverseEventsModule": {
      "frequencyThreshold": "0",
      "timeFrame": "Adverse event data was collected for a total of 2 months while subjects were on treatment/placebo.",
      "eventGroups": [
        {
          "id": "EG000",
          "title": "Sublingual Allergen Tablets",
          "description": "Subjects will be administered a sublingual allergen tablet customized to their individual allergic sensitization.\n\nallergen extract tablet: 1 allergen extract tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet",
          "deathsNumAffected": 0,
          "deathsNumAtRisk": 10,
          "seriousNumAffected": 0,
          "seriousNumAtRisk": 10,
          "otherNumAffected": 1,
          "otherNumAtRisk": 10
        },
        {
          "id": "EG001",
          "title": "Placebo",
          "description": "Subjects will be administered placebo sublingual tablets\n\nPlacebo tablet: 1 placebo tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet",
          "deathsNumAffected": 0,
          "deathsNumAtRisk": 9,
          "seriousNumAffected": 0,
          "seriousNumAtRisk": 9,
          "otherNumAffected": 0,
          "otherNumAtRisk": 9
        }
      ],
      "otherEvents": [
        {
          "term": "Throat irritation and ear fullness",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 10
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 9
            }
          ]
        }
      ]
    },
    "moreInfoModule": {
      "certainAgreement": {
        "piSponsorEmployee": true
      },
      "pointOfContact": {
        "title": "Dr. Brant Ward",
        "organization": "Virginia Commonwealth University",
        "email": "brant.ward@vcuhealth.org",
        "phone": "804-828-1941"
      }
    }
  },
  "documentSection": {
    "largeDocumentModule": {
      "largeDocs": [
        {
          "typeAbbrev": "Prot_SAP",
          "hasProtocol": true,
          "hasSap": true,
          "hasIcf": false,
          "label": "Study Protocol and Statistical Analysis Plan",
          "date": "2013-04-25",
          "uploadDate": "2022-02-21T12:20",
          "filename": "Prot_SAP_000.pdf",
          "size": 4843523
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D065631",
          "term": "Rhinitis, Allergic"
        }
      ],
      "ancestors": [
        {
          "id": "D012220",
          "term": "Rhinitis"
        },
        {
          "id": "D009668",
          "term": "Nose Diseases"
        },
        {
          "id": "D012140",
          "term": "Respiratory Tract Diseases"
        },
        {
          "id": "D012130",
          "term": "Respiratory Hypersensitivity"
        },
        {
          "id": "D010038",
          "term": "Otorhinolaryngologic Diseases"
        },
        {
          "id": "D006969",
          "term": "Hypersensitivity, Immediate"
        },
        {
          "id": "D006967",
          "term": "Hypersensitivity"
        },
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "D000485",
          "term": "Allergens"
        }
      ],
      "ancestors": [
        {
          "id": "D000941",
          "term": "Antigens"
        },
        {
          "id": "D001685",
          "term": "Biological Factors"
        }
      ]
    }
  },
  "hasResults": true
}